SCHEMBL3863733

SCHEMBL3863733

CC(C)CC(=O)Nc1ccc2oc3c(c2c1)CCC3

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
RXFP1 Q9HBX9 1/20 0.52
LMNA P02545 1/20 0.50
KMT2A Q03164 2/20 0.49
TP53 P04637 2/20 0.48
GAA P10253 1/20 0.47
PTPN1 P18031 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866945 0.98 MAPT (0.59) MAPTRAB9ANPC1SMN1; SMN2CYP1A2
SCHEMBL3865920 0.96 MAPT (0.58) MAPTRAB9ANPC1SMN1; SMN2CYP1A2
SCHEMBL3863467 0.96 MAPT (0.58) MAPTRAB9ANPC1SMN1; SMN2CYP1A2
SCHEMBL3863032 0.86 MAPT (0.57) MAPTNPC1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3862354 0.84 MAPT (0.62) MAPTNPC1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3863470 0.83 MAPT (0.52) MAPTRAB9ANPC1SMN1; SMN2CYP1A2
SCHEMBL3868769 0.83 MAPT (0.56) MAPTNPC1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3863835 0.82 MAPT (0.61) MAPTNPC1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3863940 0.82 MAPT (0.61) MAPTNPC1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL3864891 0.81 MAPT (0.54) MAPTRAB9ANPC1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601856-B2 Benzofurans as potassium ion channel modulators WYETH (US) 2009-10-13 US claimed
US-20080027049-A1 Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide WYETH (US) 2008-01-31 US claimed
US-7601856-B2 Benzofurans as potassium ion channel modulators WYETH (US) 2009-10-13 US disclosed
US-7601856-B2 Benzofurans as potassium ion channel modulators WYETH (US) 2009-10-13 US disclosed
US-7601856-B2 Benzofurans as potassium ion channel modulators WYETH (US) 2009-10-13 US disclosed
US-20080027049-A1 Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide WYETH (US) 2008-01-31 US disclosed
US-20080027049-A1 Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide WYETH (US) 2008-01-31 US disclosed
US-20080027049-A1 Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide WYETH (US) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027049-A1 Such as 2,2-Dimethyl-N-(6,7,8,9-tetrahydro-dibenzofuran-2-yl)-propionamide KCNJ2, KCNJ5, KCNA5 MAPT 2740/4885RAB9A 3161/4885NPC1 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.